Services Core/facility: Precision Cancer Modeling

In vivo cancer models

Vish Muthusamy, PhD

About the services

Jump to Cell line-derived xenograft (CDX) models — Patient-derived xenograft (PDX) models — Syngeneic models — Genetically engineered mouse models (GEMMS) — Metastasis models

Cell line-derived xenograft (CDX) models

These experiments typically involve engrafting human cancer cell lines into mice, followed by intervention with a therapeutic agent. Our repository includes a wide range of human cell lines across multiple cancer types, all validated for tumor formation in immunodeficient mouse strains. With comprehensive historic growth data, we can recommend optimal therapeutic windows and define experimental endpoints to demonstrate efficacy. Our experience with standard-of-care drugs in select models also enables the design of combination strategies. Additionally, we can characterize and conduct experiments using investigator-provided engineered cell lines or commercially sourced lines. [Back to top]

Plots of tumor volume and survival with two drug treatments
Combinational treatment by erdafitinib and quisinostat can enhance anti-tumor effects and prolong survival of BC with FGFR3 fusions in vivo. Source: Wang et al., 2023

Patient-derived xenograft (PDX) models

PDX models are generated using primary human tumor material that has never been exposed to plastic. As a result, these tumors have not undergone the selection pressures associated with in vitro culture and therefore more faithfully recapitulate human tumor biology, excluding the immune compartment. We have extensive experience establishing new PDX models across multiple cancer types and optimizing graft take in immunodeficient host mice. In addition, we have conducted large-scale preclinical efficacy studies of promising therapeutic agents that have subsequently demonstrated clinical success. [Back to top]

PDX panel
Source: PCM internal data (unpublished)

Syngeneic models

These models are grafted into fully immunocompetent, syngeneic host mice and are therefore well suited for evaluating therapeutics and strategies that target immune pathways. A substantial portion of PCM’s experience lies in the use of these models, and we can assist in designing rigorous experiments to assess relevant immunotherapies. A wide range of standard-of-care immune-based treatments (checkpoint inhibitors, cytokines, immune cell–specific antibodies, and antibody–drug conjugates) have been tested in these systems, generating data that can be leveraged to develop and evaluate novel combination strategies. PCM is fully equipped to monitor and characterize immune responses throughout the course of these studies, including cytokine profiling and analysis of tumor-infiltrating immune populations, using established platforms and methodologies. [Back to top]

Six plots of tumor volume and survival following drug treatment
Intratumoral injection of SLR14 results in significant antitumor effect. Source: Jiang et al., 2019
6 images of groups of mice before vs after drug treatment for a tumor
Source: PCM internal data (unpublished)

Genetically engineered mouse models (GEMMS)

Genetically engineered mouse models (GEMMs) are designed to recapitulate disease initiation and progression and are powerful tools for understanding tumor biology and disease course. At PCM, we identify the most appropriate GEMM for the scientific question at hand and manage all aspects of model execution, including breeding, genotyping, cohort establishment, and other required manipulations to support rigorous preclinical studies. [Back to top]

Diagram of mice with vs without a gene and effect on melanoma growth
DNA methyltransferase DNMT3B loss dramatically suppresses melanoma formation in the Braf/Pten mouse melanoma model. Source: Micevic et al., 2016
Diagrams of mice with variable phenotypes
Source: Dankort et al., 2009

Metastasis models

PCM has developed and optimized multiple in vivo models that reflect metastatic disease. These models are particularly valuable for evaluating therapeutic efficacy in advanced-stage cancers involving metastases to distant organs, as well as for assessing potential abscopal effects. Available approaches include grafting or GEMM-based spontaneous metastasis models, vascular introduction of cancer cells and orthotopic implantation. Disease progression and treatment response in these models can be assessed using noninvasive imaging modalities such as bioluminescence, fluorescence, and magnetic resonance imaging or through serial histopathological evaluation. [Back to top]

5 photos of mice showing metastatic spread
Source: PCM internal data (unpublished)
Plot of metastatic burden vs days post injection
Source: PCM internal data (unpublished)
4 plots of metastatic burden versus time in different organs
Source: PCM internal data (unpublished)

Available to Yale researchers & external researchers